The last decade has ushered rapid advances in modeling, toxicogenomics, bioinformatics, epigenetics, imaging as well as computational pharmacology and toxicology, to name a few. Great emphasis has also been placed on addressing the utility of in vitro methods and complimentary in vivo animal models to advance the understanding of neuropharmacology and neurotoxicity, while concomitantly reducing the need for mammals in experimentation. Emphasis has also been placed on genetics/transgenic models with inherent high throughput capacity to accelerate the identification of candidate genes that modulate toxic outcomes and pharmacokinetics. Altogether, the issue provides state-of-the-art account on emerging methods and mechanisms by which pharmacological and environmental compounds mitigate or trigger neurological disorders, respectively Foreword to Special Issue on Neuropharmacology and Neurotoxicity, Michael Aschner.
Journal of clinical toxicology as a bimonthly open access journal focuses mainly on the advancements in the field of toxicology research and thus publishes review articles highlighting this issue. But on the same time we consider only articles with provocative discussions and excellent references. The acceptances of these articles are finally based on editors decisions. Thus through our review articles we are trying to highlight the research advancements in this field of science.
Last date updated on June, 2014